Plate Nº 38 · recorded October 3, 2026
Health & Medicine ResearchReported finding
Experimental Pill Trial Aims to Slow Congo's Deadliest Ebola Outbreak
A trial in eastern Congo is testing obeldesivir, a Gilead antiviral pill given after exposure to Ebola. Over 250 people have joined the study.
By Priya Raman4 min read701 words
In brief
- The trial in Ituri province has enrolled more than 250 people and aims to recruit nearly 1,000 participants; half receive a placebo.
- The outbreak, driven by the Bundibugyo virus, has recorded at least 8,300 confirmed cases and 4,000 deaths across seven provinces since mid-May.
- The WHO says the outbreak is set to exceed West Africa's 2014-2016 epidemic, the deadliest on record, which killed 11,000 people.
More than 250 people have enrolled in a clinical trial testing a pill that could stop them from developing Ebola, in what experts call a critical step against the deadliest outbreak of the disease ever recorded in Congo.
The trial, which began in July, is testing obeldesivir, an experimental antiviral drug developed by the American pharmaceutical company Gilead. Doctors give the pill shortly after suspected contact with the virus, an approach known as post-exposure prophylaxis, or PEP. In plain terms, the goal is to prevent the disease from taking hold in people who may already carry the virus but do not yet feel sick.
The outbreak is driven by the Bundibugyo virus, a species of Ebola that currently has no approved vaccine or treatment. Since Congolese authorities declared the outbreak in mid-May, eastern Congo has recorded at least 8,300 confirmed cases and 4,000 deaths. The disease has spread to seven provinces and continues to outpace efforts to track and slow it, according to officials.
The trial is taking place at a health center in Ituri province, the epicenter of the outbreak. Participants include people exposed during this outbreak—among them health workers and relatives of patients. One woman told the Associated Press she enrolled in August after her husband tested positive for Ebola. So far, no one in her family has developed symptoms. She and other participants requested anonymity because of the sensitive nature of the outbreak.
Another participant said two family members had caught Ebola, and one had died. "This disease is killing. It's better to take precautions," he said.
How the trial works
The medical nonprofit ALIMA coordinates the study, alongside Congo's National Institute of Biomedical Research and the French institute ANRS Emerging Infectious Diseases. The researchers aim to recruit nearly 1,000 adults and children over the age of 12 who came into contact with a confirmed case within the last five days but show no symptoms. Half of the participants receive a placebo, a dummy pill with no active ingredient.
Participants receive in-person monitoring every day for 21 days, followed by a final phone call after 42 days, according to Dr. Godefroid Basara, who works on the trial. If participants begin to develop symptoms, they immediately receive supportive treatment, which ALIMA says helps when symptoms are caught early.
The drug is designed to act fast. "It differs from a vaccine, which may take days or weeks to provide protection. It is also different from curative treatment because it is intended for people who are not yet showing symptoms," said Dr. Guilavogui Jean Paul Yassa, ALIMA's research coordinator. If the pill proves effective, it could break the chain of infection.
Those are big ifs, and the results remain preliminary. The study is still recruiting, and researchers have not yet reported whether obeldesivir actually prevents illness.
The work faces practical hurdles, too. Dr. Jacques Zawadi, an investigating physician with ALIMA at the trial center, said most participants are glad to take part, but convincing people who live far from the center has been difficult. The study is sometimes disrupted when participants learn that family members have died from the disease. "When a person is emotionally affected, it is not easy to reason with them and ensure they return to the study," he said.
Health workers at risk
Front-line medical staff remain especially vulnerable. On Thursday, Doctors Without Borders said one of its staff members had tested positive for Ebola and was being evacuated to the Netherlands. In June, a humanitarian physician with ALIMA tested positive after returning to France from one of the hot spots.
Congo has started vaccinating health workers with the Ervebo vaccine, which proved effective during earlier outbreaks caused by a different, more common Ebola virus. Authorities say Ervebo might offer some protection against Bundibugyo, but whether it actually prevents illness remains under study.
The stakes are high. The World Health Organization has said the outbreak continues to outpace containment efforts and is set to exceed West Africa's 2014–2016 regional epidemic, the deadliest on record, which killed 11,000 people. Whether obeldesivir can help slow it is a question the Ituri trial may help answer.
via Medical Xpress (Source)
More from Priya Raman
Show full bio
Senior reporter covering industry trends and analytics at SciBeat.
57 articles
Nearby plates
- Scientists Map Three Weak Points in Antibiotic-Resistant Bacteria
- Scientists Find a Way to Kill a Drug-Resistant Deadly Fungus
- FDA Urges Drug Makers to Release Data From Thousands of Unpublished Trials
- Resistance Gene Helps C. difficile Survive Hospital Disinfectants
- Alzheimer's Drug Developers Accuse Trial Sites of Faking Data